Buy B7-33 Europe
Buy B7-33 Europe. Single-chain relaxin-2 analogue for fibrosis and cardiovascular research. ≥99% purity. Fast EU delivery.
What is B7-33?
B7-33 is a single-chain peptide analogue derived from residues 7–33 of the B-chain of human relaxin-2. Unlike native relaxin-2—a complex two-chain, three-disulfide-bond insulin-like peptide—B7-33 is a simplified linear peptide that retains the ability to activate the relaxin family peptide receptor 1 (RXFP1). For published research, see PubMed studies on B7-33 relaxin{:target=“_blank” rel=“noopener”}.
Its simplified structure makes B7-33 significantly easier to synthesise than native relaxin-2 while maintaining biologically relevant RXFP1 agonist activity, making it a valuable research tool for studying anti-fibrotic, vasodilatory, and cardioprotective mechanisms.
Best-Peptides supplies research-grade B7-33 with guaranteed ≥99% purity and full analytical documentation.
How Does B7-33 Work?
RXFP1 Receptor Activation
- RXFP1 agonism - Selective activation of relaxin family peptide receptor 1
- Gs protein coupling - Adenylyl cyclase stimulation and cAMP production
- Gi/o signalling - Secondary G-protein pathway activation
- Biased agonism - Potentially distinct signalling profile from native relaxin
Anti-Fibrotic Mechanisms
- MMP upregulation - Matrix metalloproteinase-2 and -9 activation
- Collagen degradation - Enhanced extracellular matrix turnover
- TGF-β suppression - Reduced profibrotic cytokine signalling
- Myofibroblast inhibition - Reduced α-SMA expression
Vascular and Cardioprotective Effects
- Nitric oxide synthesis - nNOS and iNOS activation
- Vasodilation - Vascular smooth muscle relaxation
- Cardiac remodelling - Anti-hypertrophic signalling
Research Applications
Fibrosis Research
- Cardiac fibrosis - Collagen turnover and MMP activation studies
- Renal fibrosis - Tubular and interstitial fibrosis models
- Hepatic fibrosis - Stellate cell activation modulation
Cardiovascular Biology
- Vasodilation - Endothelium-dependent relaxation studies
- Cardiac protection - Ischemia-reperfusion injury models
- Vascular remodelling - Arterial stiffness and compliance
Relaxin Receptor Pharmacology
- RXFP1 characterisation - Receptor binding and activation studies
- Structure-activity relationships - Single-chain vs two-chain comparisons
- Biased signalling - G-protein selectivity profiling
B7-33 Specifications
| Specification | Detail |
|---|---|
| CAS Number | Not assigned |
| Molecular Formula | Truncated relaxin-2 B-chain |
| Molecular Weight | ~3600 Da |
| Sequence | Human relaxin-2 B-chain residues 7-33 |
| Purity | ≥99% (HPLC) |
| Appearance | White lyophilised powder |
Reconstitution and Handling
Reconstitution Protocol
- Allow vial to reach room temperature
- Add bacteriostatic water slowly down vial wall
- Gently swirl—do not shake
- Solution should be clear
Storage Recommendations
| Condition | Temperature | Duration |
|---|---|---|
| Lyophilised | -20°C | Up to 24 months |
| Reconstituted | 2-8°C | Up to 4 weeks |
Ordering Information
| Size | Price |
|---|---|
| 10 × 2 mg | €350 |
Minimum order: €200 | 10% discount on orders over €200
Why Choose Best-Peptides for B7-33?
- Guaranteed ≥99% purity - HPLC verified
- Full documentation - COA with every order
- EU laboratory tested - Quality assured
- Fast delivery - Express shipping available across Europe
- Research support - Technical assistance
Research Use Statement
For laboratory research only. Not intended for human or veterinary use. Researchers should follow all applicable regulations.
Specifications
| CAS No. | |
|---|---|
| Molecular Weight | ~3600 Da |
| Purity | ≥ 99% |
| Storage | -20°C recommended (research-only) |
| Available Sizes | 10 × 2 mg vials |
| Price Range | €350 per pack |
FAQ
B7-33 is studied as a simplified, single-chain analogue of human relaxin-2 that selectively activates RXFP1 signalling. Research focuses on anti-fibrotic mechanisms, cardiovascular protection, vascular remodelling, and collagen turnover.
B7-33 is a truncated single-chain peptide derived from residues 7-33 of the relaxin-2 B-chain. Unlike native relaxin-2, which requires complex two-chain folding with three disulfide bonds, B7-33 is simpler to synthesise while retaining RXFP1 agonist activity.
B7-33 activates the relaxin family peptide receptor 1 (RXFP1), which couples to Gs and Gi/o proteins. This triggers cAMP production, nitric oxide synthesis via nNOS/iNOS, and activation of matrix metalloproteinases that degrade excess extracellular matrix.
Store lyophilised B7-33 at -20°C for long-term stability. Once reconstituted, keep at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.
Our B7-33 is ≥99% pure as verified by HPLC. Each batch includes a Certificate of Analysis with purity data and mass spectrometry identity confirmation.
Yes, B7-33 is commonly compared with native relaxin-2, serelaxin, and other anti-fibrotic agents. Its single-chain structure makes it particularly useful for structure-activity relationship studies.
Reconstitute in sterile bacteriostatic water or PBS. Add solvent slowly along the vial wall and gently swirl to dissolve. B7-33 dissolves readily in aqueous solution.
B7-33 is available in 2 mg vials, supplied as a pack of 10 × 2 mg for research applications.
Customer Reviews (12)
Based on 12 reviews
Dr. Thomas Gruber • 2025-11-15Verified Purchase
B7-33 reliably activates RXFP1 in our cardiac fibroblast assays. Anti-fibrotic signalling is clearly dose-dependent and reproducible.
Leiden Cardiovascular Research • 2025-10-29Verified Purchase
The simplified structure of B7-33 makes it ideal for our SAR studies. MMP upregulation and collagen reduction are clearly demonstrable.
Dr. Nathalie Garnier • 2025-10-12Verified Purchase
Fast delivery to France, superb purity. Our organ fibrosis research is advancing rapidly with this product.
Freiburg Cardiology Research Lab • 2025-09-25Verified Purchase
Consistent quality for our vascular remodelling studies. cAMP and NO production profiles match expected relaxin-like activity.
Dr. Roberto Esposito • 2025-09-08Verified Purchase
Verified RXFP1 activation by cAMP reporter assay. Collagen I expression is significantly reduced in our cardiac fibrosis model.
Aarhus Fibrosis Research Group • 2025-08-22Verified Purchase
B7-33 single-chain design simplifies our experimental protocols. Biological activity is comparable to two-chain relaxin controls.
Dr. Katarzyna Mazur • 2025-08-05Verified Purchase
Arrived within 3 days. Product quality excellent for our renal fibrosis research.
Salzburg Vascular Biology Lab • 2025-07-19Verified Purchase
B7-33 performs well in our vasodilation studies. Nitric oxide synthesis is clearly enhanced.
Dr. Lars Pedersen • 2025-07-02Verified Purchase
Excellent for RXFP1 pharmacology and fibrosis pathway research. Quality documentation is comprehensive.
Madrid Regenerative Medicine Lab • 2025-06-15Verified Purchase
Consistent across multiple batches. Our extracellular matrix remodelling studies produce robust results.
Dr. Hanna Virtanen • 2025-05-29Verified Purchase
Easy ordering, quick delivery to Finland. B7-33 biological activity verified in our own bioassays.
Geneva Cardiovascular Institute • 2025-05-12Verified Purchase
High-quality single-chain relaxin analogue with complete analytical documentation. Highly recommended for fibrosis and cardiovascular researchers.
Related Products
View Complete Catalog
